YTHDF2 and cancer: YTHDF1, along with YTHDF2 and YTHDF3, redundantly suppresses the IFN‐γ response by destabilizing IRF1 mRNA, suggesting that these proteins can serve as viable therapeutic targets in cancer immunotherapy.